CD274 and non-small cell lung carcinoma: The CITYSCAPE trial randomized 135 treatment naïve patients, with advanced PD-L1 positive NSCLC, to atezolizumab vs. tiragolumab+atezolizumab, obtaining good ORR and PFS, especially in the PD-L1 ≥50% (66% for combination versus 24% for atezolizumab) (55).